Trinity Delta view: In line with its guidance, MaxCyte has disclosed encouraging tolerability data for the first cohort of the MCY-M11 Phase I study, which in tandem has validated its manufacturing process.
A key goal of the Phase I study is to confirm the potential of CARMA therapies, particularly in solid tumours where there are currently limited treatment options. It is reassuring that there are no major tolerability issues associated with the initial dosing of the first CARMA therapy, although a better indication of MCY-M11’s potential should become apparent later this year, once safety and efficacy data from the higher dose cohorts becomes available. This trial will also provide the first indication in patients whether CARMA therapies can have a significant anti-tumour effect while avoiding severe on-target/off-tumour toxicities, which limits the potential protein targets of current CAR-T approaches.
Another key issue affecting the wider adoption of CAR-T therapies is manufacturing. The CARMA process can be carried out in the hospital and avoids the expansion step, so has cost and time advantages. The MCY-M11 Phase I trial has validated MaxCyte’s process and shown that it can be carried out in a single day, in comparison it takes one-to-two weeks for Novartis’ Kymriah and Kite’s Yescarta.
We expect further data from the MCY-M11 Phase I study later in 2019, and highlight that a second CARMA trial, with an intravenous formulation of MCY-M11, remains on track for initiation in H219.
We value MaxCyte at £195m or 341p per share.
Lighthouse
8 May 2019
| Price | 180p |
| Market Cap | £92m |
| Primary exchange | AIM London |
| Sector | Healthcare |
| Company Code | MXCT |
| Corporate client | Yes |
Company description
MaxCyte uses its patented flow electroporation platform to transfect a wide array of cells. Revenues arise from sale and lease of equipment, disposables and licence fees; with an impressive client list. Additionally, a novel mRNA mediated CAR technology, known as CARMA, is being explored in various cancers, including solid tumours.
Analysts
Mick Cooper PhD
mcooper@trinitydelta.org
+44 (0) 20 3637 5042
Lala Gregorek
lgregorek@trinitydelta.org
+44 (0) 20 3637 5043
Disclaimer
Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.
ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.
In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.
Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.
This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.
Copyright 2019 Trinity Delta Research Limited. All rights reserved.